

ASTRAZENECA PLC
Form 6-K
September 28, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For the month of September 2016

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____

28 September 2016 07:00

CHANGE TO ASTRAZENECA BOARD OF DIRECTORS

AstraZeneca today announced that Dr Cornelia (Cori) Bargmann, a Non-Executive Director, will step down from the Board of AstraZeneca PLC and as a member of the Company's Science Committee with effect from 1 October 2016. Dr Bargmann recently accepted a new position as President of Chan Zuckerberg Science, part of the Chan Zuckerberg Initiative.

Leif Johansson, AstraZeneca Chairman, said: "We congratulate Cori on her new appointment and thank her for her contribution to AstraZeneca in the last 18 months. We are sorry to see her leave the AstraZeneca Board but fully understand her decision to step down to focus on her new assignment."

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries

| | | |
|------------------|-----------|------------------|
| Neil Burrows | UK/Global | +44 203 749 5637 |
| Vanessa Rhodes | UK/Global | +44 203 749 5736 |
| Karen Birmingham | UK/Global | +44 203 749 5634 |
| Rob Skelding | UK/Global | +44 203 749 5821 |
| Jacob Lund | Sweden | +46 8 553 260 20 |
| Michele Meixell | US | +1 302 885 2677 |

Investor Relations

UK

| | | |
|---------------------|----------------------------|------------------|
| Thomas Kudsk Larsen | | +44 203 749 5712 |
| Craig Marks | Finance, Fixed Income, M&A | +44 7881 615 764 |
| Nick Stone | Respiratory & Autoimmunity | +44 203 749 5716 |
| Henry Wheeler | Oncology | +44 203 749 5797 |
| Christer Gruvris | Infection & Neuroscience | +44 203 749 5711 |

US

Edgar Filing: ASTRAZENECA PLC - Form 6-K

| | | |
|------------------|-------------------------------------|-----------------|
| Lindsey Trickett | Cardiovascular & Metabolic Diseases | +1 240 543 7970 |
| Mitchell Chan | Oncology | +1 240 477 3771 |
| Toll-free | | +1 866 381 7277 |

Adrian Kemp
Company Secretary
AstraZeneca PLC

-ENDS-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

Date: 28 September 2016

By: /s/ Adrian Kemp
Name: Adrian Kemp
Title: Company Secretary